This is the authors' abstract. We don't add key points for this paper.
Pain has a way of clipping our wings and keeping us from being able to fly … and if left unresolved for very long, you can almost forget that you were ever created to fly in the first place. William Paul Young The Shack, published 2007 In April, 1907, the young man reported that he had been laid up in a hospital from December 26, 1906, to February 26, 1907, with what he called muscular rheumatism. His illness had begun with malaise, pain in the back, the muscles of the legs and arms. J.B. Herrick Arch Intern Med 1910;5:517 … relentless and repetitive gnawing pains in the bones and joints characteristic of the disease. F.I.D. Konotey-Ahulu Arch Intern Med 1974;133:611 Pain, the symptom that typifies sickle cell disease, has the frightful capacity to strip life of all aspirations. Those who experience the inveterately painful existence of sickle cell disease often lead lives defined by their relationship with their pain; those with inadequate coping skills have lives filled with frustration, dissocial adaptations, isolation, and depression [1]. The pain crises of sickle cell disease have been described as rather brief episodes that last from hours to a few days [2] and occur relatively infrequently [3,4]. This notion differs greatly from the 2-month ordeal experienced by patient Walter Clement Noel, as described above by intern Ernest E. Irons to Dr. J.B. Herrick [5]. The translation above by Dr. F.I.D. Konotey-Ahulu of the African tribal descriptor of sickle cell pain, chwecheechwe, indicates that these “… repetitive gnawing pains in the bones …” are far worse than passing discomfort [6]. The pain experienced by patients with sickle cell disease varies widely, and its quantification for studies of disease severity and responses to new therapies has been difficult for scientists, regulatory agencies, and potential investors in drug development. In this issue of Pain Medicine, Dr. Smith and his associates may have provided opportunities for new regulatory endpoints [7]. Their study was a reanalysis of the data generated by the gold standard trial of sickle cell disease pain prevention, the Multicenter Study of Hydroxyurea (MSH) as treatment of pain in sickle cell disease [8]. The original MSH used traditional methods for detecting pain crises to find that hydroxyurea therapy reduced the frequency of acute painful episodes. Using different measurements of pain, the current investigators established that hydroxyurea also reduced the daily pain score, analgesia use, and health care utilization, particularly in those subjects who had the largest increment in fetal hemoglobin (HbF) levels. Their finding of a highly significant correlation of the small decrement in daily pain score with the MSH pain frequency data suggests that such small daily decrements in pain score could be acceptable regulatory end points. The forthright admission by these investigators that their measured decrements in daily pain score are less than perceptible by a human. This writer suggests, rather, that this finding defines why we do not conduct N = 1 studies; a clinical trial of a new sickle cell disease treatment could logically accept small decrements in daily pain score as a regulatory end point if the study were adequately powered. The history of sickle cell pain assessment provides appreciation of the current work. Early attempts at quantifying the pain of sickle cell disease simplified things by using the frequency of acute painful episodes as the standard measure of pain for natural history studies [4] and drug development trials [8]. The frequency of acute painful episodes was determined using plain criteria: seeking medical care, visiting a doctor's office, going to the emergency ward, or being hospitalized. Regulatory agencies, too, adopted these criteria as outcome measures for trials of candidate sickle cell disease therapies. As a result, studies that require frequency of pain episodes as the single clinical end point are by necessity large, costly, and challenging. In addition to the perceived requirement by regulatory agencies of this demanding end point was the general belief within business and investment communities that satisfying this criterion was necessary for regulatory approval. Thus, procuring private funding for early stage pharmaceutical companies targeting sickle cell disease became very challenging. In this context, approaches to treating sickle cell disease pain evolved. Greater numbers of patients with acute pain were treated in their homes [9]. While patients prefer this approach to visiting emergency departments, home treatment introduces considerable subjectivity into scientific measurements of disease severity. “Interruption of the activities of daily living” is semi-quantitative, at best. Concomitant with changing standards of care came a whole new language of pain. Derived from the approaches of social scientists and the use of pain diaries came new distinctions, including perceived acute pain crises, unscheduled utilization of health care delivery, maximum daily pain, and home opiate use [9]. Also came understandings that absence of crisis is not absence of pain, health care utilization is not synonymous with pain crisis, utilization is not necessary for opiate use, and pain may be more chronic than what had been believed. As the potential of these insights for measuring disease severity evolved, surrogate markers of vascular and inflammatory perturbations [10], markers of neuropathic and inflammatory pain [11], microfluidics methods for assessing changes in blood flow ex vivo[12,13] and metabolomic erythrocyte profiles [14] have also materialized as potential markers for quantifying disease severity and responses to new drugs. The preeminence of impaired microvascular blood flow in determining disease morbidity [15] underscores the logic of using the measurement of microvascular blood flow in vivo, the most suitable method for which is the laser Doppler method [16], as a surrogate marker of disease severity. The additional finding by Dr. Smith and his associates that even the best responders in daily pain score had residual pain that greatly exceeded hydroxyurea-induced decrements in pain defines the need for better therapies. Their finding that contemporary measures for quantifying pain correlate significantly with traditional criteria suggests a new, less arduous but valid set of regulatory end points. In the continuum from the use of disease mortality to quantify life, through the use of frequency of pain crises to approximate quality of life, these investigators have brought us to true measures of quality of life; quality of life is the endpoint endorsed by regulatory agencies. While perhaps not the original goal of the current study, the findings of Smith et al. may in the long run influence regulatory policy and facilitate drug development. We can only hope that the regulatory and investment communities are still paying attention to academic studies of pain.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Stephen H. Embury (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: